Breaking News Instant updates and real-time market news.

TEVA

Teva

$18.73

-0.54 (-2.80%)

, MNTA

Momenta

$16.30

0.05 (0.31%)

10:21
02/13/18
02/13
10:21
02/13/18
10:21

Teva generic comes earlier than expected, says Wells Fargo

Wells Fargo analyst David Maris says Momenta Pharmaceuticals' (MNTA) generic approval of Teva Pharmaceutical's (TEVA) Copaxone came earlier than expected. As recently as the Q4 conference call on February 8, Teva management expected that another generic Copaxone approval would not come until April 2018, Maris tells investors in a research note. The analyst's forecasts assume a continued erosion of Copaxone sales, with sales of $700M in Q1, $500M sales in Q2 and $400M in Q3 and Q4. Maris keeps an Underperform rating on Teva.

TEVA

Teva

$18.73

-0.54 (-2.80%)

MNTA

Momenta

$16.30

0.05 (0.31%)

  • 21

    Feb

TEVA Teva
$18.73

-0.54 (-2.80%)

02/12/18
02/12/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Nasdaq (NDAQ) upgraded to Outperform from Market Perform at Wells Fargo by analyst Christopher Harris, who said the company is at an inflection point where both its trading and non-trading segments will begin to generate faster growth. He sees a "pathway to much higher profit margin" over the next two years and believes the stock is "relatively inexpensive" at a discount to the S&P 500 Index. 2. Teva (TEVA) upgraded to Outperform from Neutral at Credit Suisse by analyst Vamil Divan. The analyst sees "early execution" towards the company's restructuring plan and believes its 2018 outlook is achievable. He feels expectations are now reasonable believes the upside path is now clearer. 3. Cisco Systems (CSCO) upgraded to Buy from Neutral at Nomura Instinet by analyst Jeffrey Kvaal to reflect the webscale uptick and believes tax reform and the company's recurring revenue transition provide downside protection. Kvaal believes the recent pullback in Cisco shares provides a buying opportunity. 4. Tallgrass Energy Partners (TEP) upgraded to Overweight from Equal Weight at Barclays by analyst Christine Cho, who lowered her price target to $43 from $50. The analyst said her analysis suggests a Tallgrass Energy GP (TEGP) acquisition of Tallgrass Energy Partners is the most likely scenario. She valued Tallgrass Energy Partner at $43 in this scenario. 5. VF Corp (VFC) upgraded to Buy from hold at Stifel by analyst Jim Duffy, who sees fiscal 2019 consensus estimates rising throughout the year due to fundamental strength, environmental factors, and currency. Duffy believes VF shares can sustain the premium multiple for the "foreseeable future." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/12/18
FBCO
02/12/18
UPGRADE
Target $23
FBCO
Outperform
Credit Suisse upgrades Teva to Outperform amid execution on restructuring
Credit Suisse analyst Vamil Divan upgraded Teva Pharmaceutical to Outperform from Neutral and raised his price target for the shares to $23 from $20. The analyst sees "early execution" towards the company's restructuring plan and believes its 2018 outlook is achievable. He feels expectations are now reasonable believes the upside path is now clearer.
02/11/18
FBCO
02/11/18
UPGRADE
FBCO
Outperform
Teva upgraded to Outperform from Neutral at Credit Suisse
02/09/18
02/09/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Twitter (TWTR) upgraded to Sector Perform from Underperform at RBC Capital with analyst Mark Mahaney saying the fourth quarter revenue and EBITDA were materially better than expected, and while MAU's were below consensus, DAU's grew for the first time at a double-digit rate. 2. iRobot (IRBT) upgraded to Outperform from Market Perform at Raymond James with analyst Mark Strouse saying he sees a more balanced risk/reward following the recent pullback in the shares. 3. Regeneron (REGN) upgraded to Outperform from Neutral at Baird with analyst Brian Skorney noting its selloff since last year and believes its valuation has reached a point where the selloff is overdone. 4. Teva (TEVA) upgraded to Sector Perform from Underperform at RBC Capital with analyst Randall Stanicky saying the 11% sell-off in the stock price following the company's guidance update has removed the debate around 2018 EBITDA target and sees limited downside from the current levels. 5. United Technologies (UTX) upgraded to Buy from Hold at Argus with analyst John Eade saying the company remains a leader in a number of global industries and should continue to benefit from population growth and middle class expansion in developing markets. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
MNTA Momenta
$16.30

0.05 (0.31%)

10/05/17
GSCO
10/05/17
NO CHANGE
Target $14
GSCO
Neutral
Momenta price target cut to $14 following Mylan gCopaxone approval at Goldman
Goldman analyst Dana Flanders lowered Momenta (MNTA) estimates and cut its price target on share to $14 from $18 following Mylan's (MYL) generic Copaxone approval. The analyst maintained a Neutral rating on Momenta given uncertainties on how the gCopaxone market will play out and lack of near-term pipeline catalysts.
10/04/17
10/04/17
DOWNGRADE
Target $15

Hold
Momenta downgraded after Mylan generic Copaxone approval at Stifel
As previously reported, Stifel analyst Thomas Shrader downgraded Momenta (MNTA) to Hold from Buy, saying that Mylan (MYL) receiving FDA approval of its 40 mg/mL and 20 mg/mL generic Copaxone variants is a "clear negative" for Momenta's Glatopa franchise. Based on that news, he has cut his forecast for Glatopa revenue and lowered his price target on Momenta shares to $15 from $22.
10/04/17
STFL
10/04/17
DOWNGRADE
STFL
Hold
Momenta downgraded to Hold from Buy at Stifel
10/04/17
JPMS
10/04/17
NO CHANGE
JPMS
Overweight
JPMorgan says generic Copaxone approval 'meaninful positive' for Mylan
Mylan's (MYL) generic Copaxone approval, 9-12 months ahead of investor expectations, represents a "meaningful positive" for the story and will "substantially derisk/support" upside to 2017 and 2018 estimates, JPMorgan analyst Chris Schott tells investors in a research note. The analyst reiterates an Overweight rating on the shares. For Teva (TEVA), the approval puts further pressure on the company's "already challenged" near-term earnings profile and delevering efforts, Schott writes. The analyst keeps a Neutral rating on the shares. The analyst believes the earlier than expected approval for Mylan represents a setback for Momenta Pharmaceuticals' (MNTA) generic Copaxone opportunity. Schott had assumed the company's Glatopa would be the first generic version of Copaxone 40mg to enter the market, but he notes the product has been delayed due to manufacturing issues at a Pfizer (PFE) plant handling fill/ for the drug. The analyst, however, continues to see a "large and fairly durable" generic opportunity for Glatopa. He keeps an Overweight rating on Momenta shares, which are down 27% in premarket trading to $12.75. Mylan is up 17% to $38.20 while Teva is down 15% to $15.95.

TODAY'S FREE FLY STORIES

02:35
02/20/18
02/20
02:35
02/20/18
02:35
General news
FX Update: The dollar continued to hold firm »

FX Update: The dollar…

01:50
02/20/18
02/20
01:50
02/20/18
01:50
General news
Asian Market Summary: »

Asian Market Summary:…

TECK

Teck Resources

$29.75

-0.58 (-1.91%)

22:15
02/19/18
02/19
22:15
02/19/18
22:15
Downgrade
Teck Resources rating change at Macquarie »

Teck Resources downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TECK

Teck Resources

$29.75

-0.58 (-1.91%)

22:14
02/19/18
02/19
22:14
02/19/18
22:14
Downgrade
Teck Resources rating change at Macquarie »

Teck Resources downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TECK

Teck Resources

$29.75

-0.58 (-1.91%)

22:14
02/19/18
02/19
22:14
02/19/18
22:14
Downgrade
Teck Resources rating change at Macquarie »

Teck Resources downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TECK

Teck Resources

$29.75

-0.58 (-1.91%)

22:14
02/19/18
02/19
22:14
02/19/18
22:14
Downgrade
Teck Resources rating change at Macquarie »

Teck Resources downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMG

Chipotle

$305.63

18.98 (6.62%)

22:13
02/19/18
02/19
22:13
02/19/18
22:13
Upgrade
Chipotle rating change at Stifel »

Chipotle upgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMG

Chipotle

$305.63

18.98 (6.62%)

22:12
02/19/18
02/19
22:12
02/19/18
22:12
Upgrade
Chipotle rating change at Stifel »

Chipotle upgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

H

Hyatt

$79.73

-0.02 (-0.03%)

22:09
02/19/18
02/19
22:09
02/19/18
22:09
Upgrade
Hyatt rating change at Evercore ISI »

Hyatt upgraded to In Line…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

H

Hyatt

$79.73

-0.02 (-0.03%)

22:09
02/19/18
02/19
22:09
02/19/18
22:09
Upgrade
Hyatt rating change at Evercore ISI »

Hyatt upgraded to In Line…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

FLS

Flowserve

$44.05

1.18 (2.75%)

22:07
02/19/18
02/19
22:07
02/19/18
22:07
Upgrade
Flowserve rating change at RBC Capital »

Flowserve upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

FLS

Flowserve

$44.05

1.18 (2.75%)

22:07
02/19/18
02/19
22:07
02/19/18
22:07
Upgrade
Flowserve rating change at RBC Capital »

Flowserve upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

ANAB

AnaptysBio

$126.45

6.59 (5.50%)

, SNY

Sanofi

$39.91

0.19 (0.48%)

20:02
02/19/18
02/19
20:02
02/19/18
20:02
Hot Stocks
On The Fly: Top five weekend stock stories »

Catch up on the…

ANAB

AnaptysBio

$126.45

6.59 (5.50%)

SNY

Sanofi

$39.91

0.19 (0.48%)

REGN

Regeneron

$332.15

-1.03 (-0.31%)

SNAP

Snap

$20.42

0.67 (3.39%)

GE

General Electric

$15.05

0.2 (1.35%)

DIS

Disney

$106.53

1.35 (1.28%)

GOOG

Alphabet

$1,094.80

5.28 (0.48%)

GOOGL

Alphabet Class A

$1,095.50

4.14 (0.38%)

LRCX

Lam Research

$187.91

2.2 (1.18%)

C

Citi

$76.82

-0.26 (-0.34%)

CMI

Cummins

$165.60

0.58 (0.35%)

JPM

JPMorgan

$114.68

-0.83 (-0.72%)

JNJ

Johnson & Johnson

$133.15

1.92 (1.46%)

WMT

Walmart

$104.78

1.55 (1.50%)

PFE

Pfizer

$36.26

0.55 (1.54%)

CSCO

Cisco

$44.33

0.25 (0.57%)

ABBV

AbbVie

$118.60

3.7 (3.22%)

PEP

PepsiCo

$111.06

0.09 (0.08%)

MMM

3M

$236.67

1.8 (0.77%)

BMY

Bristol-Myers

$68.96

-0.02 (-0.03%)

UTX

United Technologies

$129.26

-0.74 (-0.57%)

TXN

Texas Instruments

$104.47

-0.1 (-0.10%)

ABT

Abbott

$60.17

0.67 (1.13%)

HOV

Hovnanian

$2.24

0.12 (5.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

  • 20

    Feb

  • 21

    Feb

  • 23

    Feb

  • 23

    Feb

  • 25

    Feb

  • 26

    Feb

  • 26

    Feb

  • 27

    Feb

  • 28

    Feb

  • 28

    Feb

  • 01

    Mar

  • 05

    Mar

  • 06

    Mar

  • 06

    Mar

  • 06

    Mar

  • 07

    Mar

  • 07

    Mar

  • 07

    Mar

  • 08

    Mar

  • 08

    Mar

  • 13

    Mar

  • 18

    Mar

  • 25

    Mar

  • 28

    Mar

  • 29

    Mar

  • 29

    Mar

  • 04

    Apr

  • 13

    Apr

  • 23

    Apr

  • 02

    May

  • 03

    May

  • 30

    May

  • 14

    Jul

  • 12

    Oct

CUB

Cubic

19:34
02/19/18
02/19
19:34
02/19/18
19:34
Hot Stocks
Cubic names president, CEO Bradley Feldmann as Chairman of the Board »

Cubic Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

  • 06

    Mar

  • 07

    Mar

  • 08

    Mar

  • 14

    Jun

HCLP

Hi-Crush Partners

$12.40

0.25 (2.06%)

19:10
02/19/18
02/19
19:10
02/19/18
19:10
Earnings
Breaking Earnings news story on Hi-Crush Partners »

Hi-Crush Partners expects…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 28

    Feb

HCLP

Hi-Crush Partners

$12.40

0.25 (2.06%)

19:08
02/19/18
02/19
19:08
02/19/18
19:08
Earnings
Hi-Crush Partners reports Q4 diluted EPS 47c, consensus 51c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 28

    Feb

FSS

Federal Signal

$19.40

0.15 (0.78%)

19:04
02/19/18
02/19
19:04
02/19/18
19:04
Hot Stocks
Federal Signal declares dividend of 7c per share »

The Board of Directors of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BCE

BCE

$44.49

-0.02 (-0.04%)

19:03
02/19/18
02/19
19:03
02/19/18
19:03
Hot Stocks
BCE reports results of Series AC, AD Preferred Share conversions »

BCE announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

PRGX

PRGX Global

$7.95

0.35 (4.61%)

18:38
02/19/18
02/19
18:38
02/19/18
18:38
Hot Stocks
PRGX Global announces appointment of new Chief Product Officer »

PRGX Global announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

CRMT

America's Car-Mart

$46.25

0.6 (1.31%)

18:37
02/19/18
02/19
18:37
02/19/18
18:37
Earnings
America's Car-Mart reports Q3 revenue $$147M, consensus $136.24M »

Reports Q3 $1.82 per…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

TAX

Liberty Tax

18:30
02/19/18
02/19
18:30
02/19/18
18:30
Hot Stocks
Liberty Tax Service taps Nicole Ossenfort to be CEO »

Liberty Tax, the parent…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TAX

Liberty Tax

18:29
02/19/18
02/19
18:29
02/19/18
18:29
Hot Stocks
Shaun York to be Chief Operating Officer for Liberty Tax Service »

Liberty Tax, the parent…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TAX

Liberty Tax

18:28
02/19/18
02/19
18:28
02/19/18
18:28
Hot Stocks
Liberty Tax names Ryan Dodson Chief Strategy Officer »

Liberty Tax, the parent…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HLX

Helix Energy

18:27
02/19/18
02/19
18:27
02/19/18
18:27
Earnings
Helix Energy reports Q4 EPS 34c, may not compare consensus (1C) »

Reports Q4 revenue $163M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

EMES

Emerge Energy

$7.77

0.12 (1.57%)

, CNI

Canadian National

$76.18

-0.68 (-0.88%)

18:17
02/19/18
02/19
18:17
02/19/18
18:17
Hot Stocks
Emerge Energy Services responds to industry-wide railroad service issues »

Emerge Energy Services…

EMES

Emerge Energy

$7.77

0.12 (1.57%)

CNI

Canadian National

$76.18

-0.68 (-0.88%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 26

    Feb

  • 28

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.